12:00 AM
 | 
Feb 09, 2009
 |  BC Week In Review  |  Company News  |  Deals

NeuroSearch, GlaxoSmithKline deal

The companies added an undisclosed number of compounds to a 2003 deal to develop CNS therapeutics, which GlaxoSmithKline has an option to license. NeuroSearch is responsible for development up to and including Phase IIa testing of the new compounds, and GlaxoSmithKline will be...

Read the full 191 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >